Yipinhong Pharmaceutical Co Ltd banner

Yipinhong Pharmaceutical Co Ltd
SZSE:300723

Watchlist Manager
Yipinhong Pharmaceutical Co Ltd Logo
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
Watchlist
Price: 41.45 CNY 4.09% Market Closed
Market Cap: ¥18.7B

EV/GP

38
Current
465%
More Expensive
vs 3-y average of 6.7

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
38
=
Enterprise Value
¥16.2B
/
Gross Profit
¥529.1m

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
38
=
Enterprise Value
¥16.2B
/
Gross Profit
¥529.1m

Valuation Scenarios

Yipinhong Pharmaceutical Co Ltd is trading above its 3-year average

If EV/GP returns to its 3-Year Average (6.7), the stock would be worth ¥7.33 (82% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-85%
Maximum Upside
No Upside Scenarios
Average Downside
78%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 38 ¥41.45
0%
3-Year Average 6.7 ¥7.33
-82%
5-Year Average 5.7 ¥6.24
-85%
Industry Average 7.6 ¥8.24
-80%
Country Average 13.6 ¥14.8
-64%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
CN
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
18.7B CNY 38 -43.6
US
Eli Lilly and Co
NYSE:LLY
910.2B USD 17.4 44.1
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 8.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 6.3 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 6.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 7.4 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 5.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 160.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 5.3 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 4.2 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
117.2B USD 4.3 16.6
P/E Multiple
Earnings Growth PEG
CN
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
Average P/E: 22.4
Negative Multiple: -43.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
44.1
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

Higher than 83% of companies in China
Percentile
83nd
Based on 6 967 companies
83nd percentile
38
Low
0 — 8
Typical Range
8 — 23.3
High
23.3 —
Distribution Statistics
China
Min 0
30th Percentile 8
Median 13.6
70th Percentile 23.3
Max 17 898 541.1

Yipinhong Pharmaceutical Co Ltd
Glance View

Market Cap
18.7B CNY
Industry
Pharmaceuticals

Yipinhong Pharmaceutical Co Ltd has carved its niche in the pharmaceutical landscape of China, with its roots embedded deeply in the nation's flourishing healthcare sector. Known for its dedication to combining traditional Chinese medicinal practices with modern scientific research, the company stands out in an increasingly competitive market. Yipinhong's operations are centered around developing, manufacturing, and distributing a broad spectrum of medicinal products that adhere to the highest quality standards. By focusing on therapeutic areas such as respiratory, cardiovascular, and gastrointestinal health, they strategically align with the growing demand for reliable medicinal solutions. What makes Yipinhong truly distinctive is its investment in research and development that drives innovation. This focus not only ensures a continuous pipeline of new products but positions them as a leader in the integration of traditional remedies with cutting-edge pharmaceutical science. The company thrives on a business model that maximizes its robust distribution network, encompassing both domestic and international markets. Yipinhong capitalizes on its vast network of sales agents and partnerships with hospitals, clinics, and pharmacies to ensure its products reach consumers efficiently. This network amplifies their revenue streams by tapping into various segments within the pharmaceutical supply chain. Moreover, Yipinhong's strategic collaborations for research and development and their participation in healthcare industry events bolster their market presence and brand recognition. By maintaining a harmonious balance between traditional approaches and modern demands, Yipinhong not only captures a unique market position but also sets a benchmark in pharmaceutical excellence and innovation.

Intrinsic Value
8.85 CNY
Overvaluation 79%
Intrinsic Value
Price ¥41.45
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett